Hoth Therapeutics Inc
NASDAQ:HOTH

Watchlist Manager
Hoth Therapeutics Inc Logo
Hoth Therapeutics Inc
NASDAQ:HOTH
Watchlist
Price: 1.04 USD -1.89% Market Closed
Market Cap: 16.1m USD

Hoth Therapeutics Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Hoth Therapeutics Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Hoth Therapeutics Inc
NASDAQ:HOTH
Free Cash Flow
-$10m
CAGR 3-Years
2%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Free Cash Flow
$19.6B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Free Cash Flow
$15.3B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
31%
Pfizer Inc
NYSE:PFE
Free Cash Flow
$10.4B
CAGR 3-Years
-24%
CAGR 5-Years
0%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Free Cash Flow
$13B
CAGR 3-Years
-5%
CAGR 5-Years
14%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Free Cash Flow
$6.4B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
14%
No Stocks Found

Hoth Therapeutics Inc
Glance View

Market Cap
15.7m USD
Industry
Pharmaceuticals

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.

HOTH Intrinsic Value
0.51 USD
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Hoth Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-10m USD

Based on the financial report for Sep 30, 2025, Hoth Therapeutics Inc's Free Cash Flow amounts to -10m USD.

What is Hoth Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-7%

Over the last year, the Free Cash Flow growth was -25%. The average annual Free Cash Flow growth rates for Hoth Therapeutics Inc have been 2% over the past three years , -7% over the past five years .

Back to Top